Myasthenia Gravis – Epidemiology – Emerging Markets
DRG Epidemiology’s coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology’s Myasthenia Gravis forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Myasthenia Gravis over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts five Myasthenia Gravis patient populations for Emerging Markets, as follows:
- Diagnosed prevalent cases
- Ocular Myasthenia Gravis
- Generalized Myasthenia Gravis
- Anti-AchR seropositive Myasthenia Gravis
- Thymoma Myasthenia Gravis
Note: coverage may vary by country.
